In this issue of the Journal of Human Hypertension we publish two letters concerning the contents of one of our supplement issues devoted to the topic of candesartan cilexetil.
1 It must be made entirely clear that papers appearing in supplement issues of the Journal, represent the proceedings of medical and scientific conferences which often cannot be peer-reviewed using the same procedures as papers submitted for the general issues. Instead we rely on the editors of the particular supplements to ensure that all papers are of sufficient standard. The criteria for the candesartan supplement were, therefore, no different from those applied to the losartan supplement we published in 1995. 
Candesartan vs losartan
In the recent article by Andersson and Neldam comparing the antihypertensive effect and tolerability of candesartan cilexetil 8 and 16 mg once-daily with that of losartan 50 mg and of placebo once-daily in patients with mild to moderate primary hypertension, the authors concluded: 'Candesartan cilexetil 16 mg is significantly more effective than losartan 50 mg once-daily, 24 h after dose administration.' 1 We believe a number of potentially serious errors have been made in this study. The losartan monotherapy dosages used in this comparison were not selected in accordance with the product circular of losartan in Sweden and Denmark, which recommends: 'The usual starting and maintenance dose is 50 mg once daily for most patients. The maximal anti-hypertensive effect is attained 3-6 weeks after initiation of therapy. Some patients may receive an additional benefit by increasing the dose to 100 mg once daily.' 2 Instead of using losartan according to the approved dosing regimen in the label, the authors incorrectly chose to compare both the candesartan 8 mg starting dose and the 16 mg maximum dose of candesartan to the starting dose of losartan (50 mg) only.
Furthermore, the trial was designed as a randomised, placebo-controlled trial. The losartan used in the study was blinded and differed from marketed losartan in two significant respects. First, the marketed losartan tablet was encapsulated in a gelatin capsule. Second, the gelatin capsule was backfilled with microcrystalline cellulose.
These blinding methods constitute a significant change in composition. Andersson and Neldam are now claiming superiority of candesartan over losartan. This should require full bioequivalence testing to demonstrate that the encapsulation of losartan did not alter the efficacy. Upon encapsulation of the losartan tablets to ensure blinding, bioequivalence with the original gelanic form was not performed, as mandated by 'The Rules Governing Medicinal Products in the European Community.' 3 Therefore, the study may be flawed and the conclusions invalid.
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